In addition, the IL-7–CBD and CBD–IL-12 combination therapy overcame resistance to PD-1 blockade in an orthotopic triple-negative breast cancer model and in a genetically engineered melanoma model. The gene discussed is IL7; the disease is triple-negative breast carcinoma.